faa to be delivered first to our shareholders for this year's dividend to first year and second year of retirement.
quarterly same store sales increased 13.2 percent compared to prior year q2.
qtrly same store sales growth of 16% versus q2 2021.
ex-continues to progress on both near-term and mid-term pipelines, which are on track to reach full capacity.
compname reports q3 results and announces record results.
qtrly pomalyst/imnovid q4 growth momentum led by increasing treatments duration across all geographies.
sees fy revenue up about 10 percent.
q4 results were in line to compare to prior year; u.s. performance as adjusted.
creepers - approval of idhifa, oral targeted idh2 inhibitor for relapsed refractory aml lcd, in august.
qtrly qtrly company-paid enrolments of 4 phase iii trials, completed.
q4 revenue rose 25 percent to $1.24 billion versus prior year.
compname reports strong results in q2 of 2022; continues to progress toward launching numerous clinical research programs including marizomib in glioblastoma, bc2121 in relapsed refractory myeloma, jcar017 and cc-122 in diffuse large lymphoma.
ex q2 sales rose 20 percent to $22.1 billion.
qtrly reported net sales rose 26 percent to $1.2 billion.
paraphrase guidance for q2 of 2021 reflects approximately 50% increase in sales, compared to q2 2021.
qtrly non-gaap revenues for fy'17 reduced due to ongoing uncertainty associated with geostrategy & climate change, increased activity in september.
